EGb761 ameliorates cell necroptosis by attenuating RIP1-mediated mitochondrial dysfunction and ROS production in both in vivo and in vitro models of Alzheimer’s disease

2020 ◽  
Vol 1736 ◽  
pp. 146730
Author(s):  
Jiang-Long Tu ◽  
Wei-Ping Chen ◽  
Zhi-Juan Cheng ◽  
Ge Zhang ◽  
Qing-Hua Luo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mitochondrial Dysfunction ◽  
In Vitro Models ◽  
Ros Production

To rectify Alzheimer's disease etiology, excessive mitochondrial division might be stopped or mitophagy might be promoted

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Mitochondrial Dysfunction ◽  
Senile Plaques ◽  
Mitochondrial Division ◽  
Disease Etiology ◽  
Abnormal Mitochondria ◽  
Unifying Principles

In both in vitro and in vivo Alzheimer's disease (AD) models, mitochondrial dysfunction is a crucial feature that limits neuronal activity and results in A and phosphorylated Tau toxicity. To rectify AD etiology, excessive mitochondrial division might be stopped or mitophagy might be promoted. However, there are still unexplained mysteries surrounding the formation of senile plaques and NFTs, and the pathophysiology of Alzheimer's disease lacks fundamental unifying principles. Some scientists believe A toxicity and Tau toxicity are upstream processes in mitochondrial dysfunction, while others feel it is a downstream chain of events involving abnormal mitochondria. There are several mitophagy mechanisms for the clearance of dead mitochondria in PINK1 signaling; some are regulated by Parkin, while others are not. Drp1, Mfn1/2, PINK1, or Parkin, according to some researchers, have no role in mitophagy cleaning dysfunctional mitochondria; so, additional study is needed to solve the puzzle of mitophagy signaling pathways for clearing dead mitochondria and conserving high-quality mitochondria. Therapeutic techniques targeting mitophagy activity might be useful in reversing AD etiology.

Neuroprotective effect of the hexapeptide HLDF-6 on rat hippocampal neurons on the in vivo and in vitro models of alzheimer’s disease

2006 ◽  
Vol 32 (4) ◽  
pp. 360-367 ◽  
Author(s):  
I. A. Kostanyan ◽  
S. S. Zhokhov ◽  
Z. I. Storozheva ◽  
A. T. Proshin ◽  
E. A. Surina ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hippocampal Neurons ◽  
Neuroprotective Effect ◽  
In Vitro Models

P1-174: Early detection of β-amyloid aggregation in in vivo and in vitro models of Alzheimer's disease

2010 ◽  
Vol 6 ◽  
pp. S224-S224 ◽  
Author(s):  
Louise A. Scrocchi ◽  
Elizabeth Karaskov ◽  
Vivian Lee ◽  
Hui Chen ◽  
Melissa Osborne ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Early Detection ◽  
In Vitro Models ◽  
Amyloid Aggregation ◽  
Β Amyloid

Thioflavin-based molecular probes for application in Alzheimer's disease: from in silico to in vitro models

Metallomics ◽  
2015 ◽  
Vol 7 (1) ◽  
pp. 83-92 ◽  
Author(s):  
C. Rodríguez-Rodríguez ◽  
M. A. Telpoukhovskaia ◽  
J. Alí-Torres ◽  
L. Rodríguez-Santiago ◽  
Y. Manso ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Silico ◽  
In Vitro Models ◽  
Molecular Probes ◽  
Drug Candidate ◽  
Chemical Tools

The proposed ThT-based drug candidate series is validated as chemical tools for further in vivo development.

Natural Anti-inflammatory compounds as Drug candidates in Alzheimer’s disease

2020 ◽  
Vol 27 ◽  
Author(s):  
Reyaz Hassan Mir ◽  
Abdul Jalil Shah ◽  
Roohi Mohi-ud-din ◽  
Faheem Hyder Potoo ◽  
Mohd. Akbar Dar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Protective Action ◽  
New Drugs ◽  
Huperzine A ◽  
Brain Disorder ◽  
Anti Inflammatory

: Alzheimer's disease (AD) is a chronic neurodegenerative brain disorder characterized by memory impairment, dementia, oxidative stress in elderly people. Currently, only a few drugs are available in the market with various adverse effects. So to develop new drugs with protective action against the disease, research is turning to the identification of plant products as a remedy. Natural compounds with anti-inflammatory activity could be good candidates for developing effective therapeutic strategies. Phytochemicals including Curcumin, Resveratrol, Quercetin, Huperzine-A, Rosmarinic acid, genistein, obovatol, and Oxyresvertarol were reported molecules for the treatment of AD. Several alkaloids such as galantamine, oridonin, glaucocalyxin B, tetrandrine, berberine, anatabine have been shown anti-inflammatory effects in AD models in vitro as well as in-vivo. In conclusion, natural products from plants represent interesting candidates for the treatment of AD. This review highlights the potential of specific compounds from natural products along with their synthetic derivatives to counteract AD in the CNS.

In vivo Evaluation and Alzheimer’s Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System

2019 ◽  
Vol 20 (1) ◽  
pp. 56-62 ◽  
Author(s):  
Chi Zhang ◽  
Zhichun Gu ◽  
Long Shen ◽  
Xianyan Liu ◽  
Houwen Lin
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Treatment Outcome ◽  
Neuroprotective Effect ◽  
Sirna Delivery ◽  
Repeated Administration ◽  
Spatial Learning And Memory ◽  
In Vivo Evaluation

Background: To deliver drugs to treat Alzheimer’s Disease (AD), nanoparticles should firstly penetrate through blood brain barrier, and then target neurons. Methods: Recently, we developed an Apo A-I and NL4 dual modified nanoparticle (ANNP) to deliver beta-amyloid converting enzyme 1 (BACE1) siRNA. Although promising in vitro results were obtained, the in vivo performance was not clear. Therefore, in this study, we further evaluated the in vivo neuroprotective effect and toxicity of the ANNP/siRNA. The ANNP/siRNA was 80.6 nm with good stability when incubated with serum. In vivo, the treatment with ANNP/siRNA significantly improves the spatial learning and memory of APP/PS1 double transgenic mice, as determined by mean escape latency, times of crossing the platform area during the 60 s swimming and the percentage of the distance in the target quadrant. Results and Conclusion: After the treatment, BACE1 RNA level of ANNP/siRNA group was greatly reduced, which contributed a good AD treatment outcome. Finally, after repeated administration, the ANNP/siRNA did not lead to significant change as observed by HE staining of main organs, suggesting the good biocompatibility of ANNP/siRNA. These results demonstrated that the ANNP was a good candidate for AD targeting siRNA delivery.

Sign in / Sign up

Export Citation Format

Share Document